Download PDF
TumorDiagnostik & Therapie 2020; 41(02): 99-107
DOI: 10.1055/a-1098-1312
Thieme Onkologie aktuell

Besonderheiten in der Nachsorge von gastrointestinalen Tumoren

Surveillance after Treatment of Gastrointestinal Cancer
Kerstin Artzner
  Medizinische Klinik I, Universitätsklinikum Tübingen, Tübingen
,
Nisar Peter Malek
  Medizinische Klinik I, Universitätsklinikum Tübingen, Tübingen
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Nach abgeschlossener Tumortherapie stellt die Nachsorge eine wichtige Säule in der Betreuung gastroonkologischer Patienten dar. Nicht nur das Erkennen und Behandeln von Folgestörungen gehört dazu, sondern auch die frühzeitige Diagnose von Rezidiven. Ein klarer Nachsorgeplan sowie eine gute Zusammenarbeit zwischen Hausärzten und den Fachdisziplinen spielen hier eine entscheidende Rolle.

Abstract

Treatment for gastrointestinal malignancies has evolved over the past two decades. Long-term outcomes have considerably improved, however a high rate of recurrence persists. With the exception of colon cancer, clear consensus strategies with regards to post-treatment surveillance are lacking. Current surveillance practices in non-colon cancer cases are inadequately based on retrospective case analyses and expert recommendations which are not uniformly consistent.

This article presents the key follow-up aspects such as recurrence frequency, timing, localization, and therapeutic efficacy for the most common gastrointestinal tumors, and summarizes current recommendations for early detection of recurrence. In particular, we compare and contrast the recommendations of the German S3 guideline, the European Society for Medical Oncology (ESMO) and the American National Comprehensive Cancer Network (NCCN).

Schlüsselwörter

Nachsorge - Tumornachsorge - Follow-up - Rezidiv - Rezidivfrüherkennung - Früherkennung - Screening - Karzinom - Krebs - Tumor - Empfehlung - S3-Leitlinie - ESMO - NCCM - Fachgesellschaften - gastrointestinale Tumore - Ösophaguskarzinom - Magenkarzinom - HCC - Hepatozelluläres - Pankreaskarzinom - Kolonkarzinom - Rektumkarzinom - Kolorektales Karzinom

Key words

cancer - carcinoma - tumor - malignancy - gastrointestinal - oncology - guideline - surveillance - follow-up - aftercare - survivorship - screening - recurrence - German Guideline Programm in Oncology - German S3 guideline - European Society for Medical Oncology - ESMO - American National Comprehensive Cancer Network - NCCN - esophageal - gastric - oesophagealgastric - AEG - panceratic - pancreas - hepatocellular - HCC - colon - colorectal


Publication History

Article published online:
02 March 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Moorcraft SY, Fontana E, Cunningham D. et al Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer 2016; 16: 112 . doi:10.1186/s12885-016-2145-0
    CrossrefPubMedGoogle Scholar
  • 2 Katz MH, Wang H, Fleming JB. et al Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 836-847 . doi:10.1245/s10434-008-0295-2
    CrossrefPubMedGoogle Scholar
  • 3 van der Stok EP, Spaander MCW, Grunhagen DJ. et al Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol 2017; 14: 297-315 . doi:10.1038/nrclinonc.2016.199
    CrossrefPubMedGoogle Scholar
  • 4 Antonowicz SS, Lorenzi B, Parker M. et al Annual computed tomography scans do not improve outcomes following esophagectomy for cancer: a 10-year UK experience. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus 2015; 28: 365-370 . doi:10.1111/dote.12209
    PubMedGoogle Scholar
  • 5 Abate E, DeMeester SR, Zehetner J. et al Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg 2010; 210: 428-435 . doi:10.1016/j.jamcollsurg.2010.01.006
    CrossrefPubMedGoogle Scholar
  • 6 Lou F, Sima CS, Adusumilli PS. et al Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer 2013; 8: 1558-1562 . doi:10.1097/01.JTO.0000437420.38972.fb
    PubMedGoogle Scholar
  • 7 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinien. Im Internet (Stand: 9.9.2017): http://www.leitlinienprogramm-onkologie.de
    PubMedGoogle Scholar
  • 8 Lordick F, Mariette C, Haustermans K. et al Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v50-v57 . doi:10.1093/annonc/mdw329
    CrossrefPubMedGoogle Scholar
  • 9 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Im Internet (Stand: 9.9.2017): https://www.nccn.org
    PubMedGoogle Scholar
  • 10 Aurello P, Petrucciani N, Antolino L. et al Follow-up after curative resection for gastric cancer: Is it time to tailor it?. World J Gastroenterol 2017; 23: 3379-3387 . doi:10.3748/wjg.v23.i19.3379
    CrossrefPubMedGoogle Scholar
  • 11 Sisic L, Strowitzki MJ, Blank S. et al Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis. Gastric cancer 2017; DOI: 10.1007/s10120-017-0751-4.
    CrossrefPubMedGoogle Scholar
  • 12 Smyth EC, Verheij M, Allum W. et al Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v38-v49 . doi:10.1093/annonc/mdw350
    CrossrefPubMedGoogle Scholar
  • 13 Ikoma N, Chen HC, Wang X. et al Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol 2017; 24: 2679-2687 . doi:10.1245/s10434-017-5838-y
    CrossrefPubMedGoogle Scholar
  • 14 Chong CS, Ng CW, Shabbir A. et al Computed tomography of the thorax for gastric cancer staging: Is it necessary?. Scand J Surg 2015; 104: 244-247 . doi:10.1177/1457496915571400
    CrossrefPubMedGoogle Scholar
  • 15 Peeters M, Lerut T, Vlayen J. et al Guideline for the esophageal and gastric cancer: scientific support of the College of Oncology. In: KCE Reports. Brussels: Belgian Health Care Knowledge Centre (KCE); 2008
    PubMedGoogle Scholar
  • 16 Baiocchi GL, D’Ugo D, Coit D. et al Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer 2016; 19: 15-20 . doi:10.1007/s10120-015-0513-0
    CrossrefPubMedGoogle Scholar
  • 17 Le AT, Tzeng CW. Does finding early recurrence improve outcomes, and at what cost?. J Surg Oncol 2016; 114: 329-335 . doi:10.1002/jso.24370
    CrossrefPubMedGoogle Scholar
  • 18 Tzeng CW, Abbott DE, Cantor SB. et al Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol 2013; 20: 2197-2203 . doi:10.1245/s10434-013-2889-6
    CrossrefPubMedGoogle Scholar
  • 19 Tzeng CW, Fleming JB, Lee JE. et al Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB: the official journal of the International Hepato Pancreato Biliary Association 2012; 14: 365-372 . doi:10.1111/j.1477-2574.2012.00445.x
    CrossrefPubMedGoogle Scholar
  • 20 Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. Onkopedia Leitlinie: Pankreaskarzinom (Juli 2017). Im Internet (Stand: 9.9.2017): https://www.onkopedia.com/de
    PubMedGoogle Scholar
  • 21 Ducreux M, Cuhna AS, Caramella C. et al Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl. 05) v56-v68 . doi:10.1093/annonc/mdv295
    CrossrefPubMedGoogle Scholar
  • 22 Robert Koch-Insitut. Zentrum für Krebsregisterdaten. Im Internet (Stand: 9.9.2017): http://www.krebsdaten.de
    PubMedGoogle Scholar
  • 23 Meniconi RL, Komatsu S, Perdigao F. et al Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 2015; 157: 454-462 . doi:10.1016/j.surg.2014.10.011
    CrossrefPubMedGoogle Scholar
  • 24 El-Serag HB. Hepatocellular carcinoma. New Engl J Med 2011; 365: 1118-1127 . doi:10.1056/NEJMra1001683
    CrossrefPubMedGoogle Scholar
  • 25 Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii41-vii48 . doi:10.1093/annonc/mds225
    CrossrefPubMedGoogle Scholar
  • 26 Makhoul R, Alva S, Wilkins KB. Surveillance and Survivorship after Treatment for Colon Cancer. Clin Colon Rectal Surg 2015; 28: 262-270 . doi:10.1055/s-0035-1564435
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Primrose JN, Perera R, Gray A. et al Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Jama 2014; 311: 263-270 . doi:10.1001/jama.2013.285718
    CrossrefPubMedGoogle Scholar
  • 28 Glynne-Jones R, Wyrwicz L, Tiret E. et al Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv22-iv40 . doi:10.1093/annonc/mdx224
    PubMedGoogle Scholar
  • 29 Labianca R, Nordlinger B, Beretta G. et al Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi64-vi72
    CrossrefPubMedGoogle Scholar